Immunologist Dr. Carl June, medical oncologist Dr. David Porter, and Loxo Oncology at Lilly CEO Dr. Josh Bilenker gathered virtually early in September to discuss Dr. Porter’s and Dr. June’s groundbreaking immunotherapy work, how work follows them home, and the course of their careers in this lively, moving discussion on what it means to care for those who are running out of hope.

Dr. Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into T cell therapies for the treatment of cancer. In 2020 he was elected to the American Philosophical Society.

Dr. David Porter is the Director of Cell Therapy and Transplantation at the Perelman School of Medicine of the University of Pennsylvania. He has been recognized by America’s Top Doctors 2007, 2008, 2010-2018, by Best Doctors in America 2009 - 2018, and Philadelphia magazine’s annual Top Docs issues, 2004 -2020. He is an expert in blood cancer, chronic lymphocytic leukemia (CLL), and leukemia.

Dr. Josh Bilenker received his M.D. from The Johns Hopkins School of Medicine and his A.B. from Princeton, awarded summa cum laude in English. Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker is CEO of Loxo Oncology at Lilly, serves as a director of Gossamer Bio, and is also a Board Member of the NCCN Foundation and of BioEnterprise.